Joon Kim J.D. serves as Director of the Company. Prior to joining Lee & Ko, Mr. Kim worked for several years as a litigation lawyer and served from 2008 to 2017 as a public prosecutor in California. Mr. Kim has first-chaired both jury and non-jury trials, and has been trained in all aspects of litigation. During his time as a public prosecutor, Mr. Kim also had the experience of serving in 2016 as a research fellow in Korea at the Institute of Justice, under the auspices of the Korea Ministry of Justice, where he worked together with Korean public prosecutors. Joon received his J.D. from Berkeley School of Law and his B.S. from the Berkeley School of Business.
Joon Kim is 54, he's been the Director of OncoSec Medical Inc since 2018. There are 6 older and 5 younger executives at OncoSec Medical Inc. The oldest executive at OncoSec Medical Inc is Margaret Dalesandro, 73, who is the Independent Chairman of the Board.
Joon's mailing address filed with the SEC is 24, North Main Street, Pennington, Mercer County, New Jersey, 08534, United States of America.
Over the last 12 years, insiders at OncoSec Medical Inc have traded over $1,474,366 worth of OncoSec Medical Inc stock and bought 9,275,650 units worth $39,853,210 . The most active insiders traders include Grand Pharmaceutical & Heal..., Holdings, Inc. Alpha oraz Robert Ward. On average, OncoSec Medical Inc executives and independent directors trade stock every 62 days with the average trade being worth of $51,563. The most recent stock trade was executed by Robert J Del Aversano on 9 February 2023, trading 40 units of ONCS stock currently worth $55.
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
OncoSec Medical Inc executives and other stock owners filed with the SEC include: